Lupin Limited (NSE:LUPIN)
India
· Delayed Price · Currency is INR 1,905.35
-72.15 (-3.65%)
Feb 21, 2025, 3:30 PM IST
Lupin Revenue
Lupin had revenue of 57.68B INR in the quarter ending December 31, 2024, with 10.97% growth. This brings the company's revenue in the last twelve months to 220.02B, up 12.94% year-over-year. In the fiscal year ending March 31, 2024, Lupin had annual revenue of 200.11B with 20.25% growth.
Revenue (ttm)
220.02B
Revenue Growth
+12.94%
P/S Ratio
n/a
Revenue / Employee
11.45M
Employees
19,210
Market Cap
870.12B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 200.11B | 33.69B | 20.25% |
| Mar 31, 2023 | 166.42B | 2.36B | 1.44% |
| Mar 31, 2022 | 164.05B | 12.43B | 8.19% |
| Mar 31, 2021 | 151.63B | -2.12B | -1.38% |
| Mar 31, 2020 | 153.75B | 7.10B | 4.84% |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
| Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 516.03B |
| Divi's Laboratories | 90.78B |
| Cipla | 267.20B |
| Mankind Pharma | 116.41B |
| Apollo Hospitals Enterprise | 211.46B |
| Zydus Lifesciences | 222.47B |
| Aurobindo Pharma | 309.22B |
| Alkem Laboratories | 127.57B |
Lupin News
- 2 days ago - Lupin’s Somerset plant gets FDA approval following successful inspection - Business Upturn
- 13 days ago - Lupin gets USFDA nod for Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% - Business Upturn
- 13 days ago - Lupin and Natco Pharma gets USFDA nod for Generic Bosentan tablets - Business Upturn
- 6 weeks ago - Lupin completes acquisition of 42.61% stake in Sunsure Solarpark - Business Upturn
- 7 weeks ago - Lupin acquires Huminsulin from Eli Lilly to strengthen its diabetes portfolio - Business Upturn
- 2 months ago - Lupin confirms tentative US FDA approval for Type-2 Diabetes drug Janumet generic - Business Upturn
- 3 months ago - Lupin and NAPCON hold walkathon for lung health - The Times of India
- 3 months ago - Lupin and Aurobindo Pharma shares in focus on positive US generics outlook; Macquarie sees potential rally - Business Upturn